SecurityOCIP / OCI Partners LP (67091N108)
IndustryChemicals And Allied Products
Institutional Owners20
Institutional Shares76,804,150 - 88.28%
Common Shares Outstanding86,997,590 shares (as of 2018-03-31)
Institutional Value$ 83,942,000 USD

Institutional Stock Ownership and Shareholders

OCIP / OCI Partners LP Institutional Ownership

OCI Partners LP (NYSE:OCIP) has 20 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 76,804,150 shares. Largest shareholders include Oci N.v., Morgan Stanley, Cowen Group, Inc., UBS Group AG, Bard Associates Inc, PCJ Investment Counsel Ltd., Quinn Opportunity Partners LLC, Deutsche Bank Ag\, Css Llc/il, and Renaissance Technologies LLC.
OCI Partners LP (NYSE:OCIP) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

File DateFormInvestor Opt Prev
Prev Value
Current Value
2018-08-14 13F-HR BARCLAYS PLC 58 58 0.00 1 1 0.00
2018-08-16 13F-HR/A COWEN GROUP, INC. 710,763 638,744 -10.13 6,503 7,346 12.96
2018-08-07 13F-HR DELTEC ASSET MANAGEMENT LLC 11,554 11,554 0.00 106 133 25.47
2018-08-14 13F-HR BANK OF AMERICA CORP /DE/ 2,500 2,500 0.00 23 29 26.09
2018-08-13 13F-HR Renaissance Technologies LLC 33,256 304
2018-08-14 13F-HR DEUTSCHE BANK AG\ 36,200 62,900 73.76 331 723 118.43
2018-08-13 13F-HR ICONIQ Capital, LLC 17,835 0 -100.00 168 0 -100.00
2017-01-13 13F-HR MetLife Securities, Inc 455 455 0.00 3 4 33.33
2018-08-13 13F-HR Worth Venture Partners, LLC 12,540 0 -100.00 115 0 -100.00
2018-08-14 13F-HR/A Quinn Opportunity Partners LLC 69,235 67,235 -2.89 634 773 21.92
2018-08-10 13F-HR CITIGROUP INC 1,842 1,842 0.00 17 21 23.53
2018-08-14 13F-HR Walleye Trading LLC 12,400 12,400 0.00 113 143 26.55
2018-08-01 13F-HR PCJ Investment Counsel Ltd. 150,000 100,000 -33.33 1,372 1,150 -16.18
2018-08-14 13F-HR GOLDMAN SACHS GROUP INC 13,824 13,824 0.00 126 159 26.19
2018-08-14 13F-HR UBS Group AG 357,606 443,231 23.94 3,272 5,097 55.78
2018-08-14 13F-HR MORGAN STANLEY 5,572,390 5,707,975 2.43 50,988 65,641 28.74
2018-08-14 13F-HR Credit Capital Investments LLC 70,300 0 -100.00 643 0 -100.00
2018-08-14 13F-HR CSS LLC/IL 51,240 589
2018-08-09 13F-HR BlackRock Inc. 3,390 39
2018-07-25 13F-HR BNP PARIBAS ARBITRAGE, SA 1 0 -100.00 9 0 -100.00
2018-05-11 13F-HR CITIGROUP INC 1,842 1,842 0.00 15 17 13.33
2016-12-06 SC 13D/A OCI N.V. 69,497,590 69,497,590 0.00
2018-08-01 13F-HR WELLS FARGO & COMPANY/MN 2,942 3,004 2.11 27 35 29.63
2018-08-14 13F-HR MANUFACTURERS LIFE INSURANCE COMPANY, THE 2,584 2,485 -3.83 24 29 20.83
2018-08-15 13F-HR BARD ASSOCIATES INC 149,675 148,625 -0.70 1,370 1,709 24.74

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

OCI N.V. (OCINF) CEO Nassef Sawiris on Q2 2018 Results - Earnings Call Transcript

2018-08-31 seekingalpha
Ladies and gentlemen, thank you all for standing by. And welcome to today’s OCI N.V. First Half 2018 Results Conference Call. At this time, all participants are in a listen-only mode. There will be a presentation followed by a question-and-answer session [Operator Instructions]. I must advise you all that this conference is being recorded today, Friday, the 31st of August, 2018.

The Nest Egg Portfolio: Adding A French Storage And Energy Distribution Specialist

2018-07-22 seekingalpha
I like the company's offered 10% discount on stock dividends - this allows shareholders to quickly expand their positions at a very advantageous price. (8-0)

Midstream Eases Higher

2018-06-25 seekingalpha
Midstream and MLPs traded well this week, but not as well as you'd expect given a 5%+ oil move and strength in income securities (like utilities). The OPEC meeting Friday turned out to be a catalyst despite no surprise, because of how well-managed expectations were. Oil, energy stocks and MLPs were sharply higher Friday, and the Dow finished positive for the first time in 9 days. (62-0)

41 'Safer' Basic Materials Top Yielding Dividends For June

2018-06-14 seekingalpha
41 of 87 Basic Materials top yield stocks were tagged "safer" for dividends because they showed positive annual returns and free cash flow yields greater than their dividend yields. (47-0)

Market Considers Pardon For Midstream

2018-06-10 seekingalpha
Midstream corporations and MLPs finished roughly where they started this week. But along the way, on Thursday, both AMZ and AMEI reached their highest levels since mid-February. The gains through Thursday slipped away Friday and the MLP Index closed back at its 200-day moving average. Midstream held up in a bad week (within a bad year) for income securities like utilities. (38-0)

OCI Partners' (OCIP) CEO Ahmed El-Hoshy on Q1 2018 Results - Earnings Call Transcript

2018-05-07 seekingalpha
Good morning. My name is Adam, and I’ll be your conference operator today. At this time, I would like to welcome everyone to the OCI Partners LP 2018 First Quarter Results Conference Call. [Operator Instructions] Thank you.

BRIEF-OCI Partners Says Q1 Revenue Rose 26 Pct To $117 Mln

2018-05-07 reuters
* OCI PARTNERS - QTRLY NET INCOME INCREASED TO $30 MILLION VERSUS $14 MILLION LAST YEAR Source text for Eikon: Further company coverage:

CUSIP: 67091N108